Rallybio

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

UCB inks $2B Candid buyout to join Gilead in autoimmune field

UCB hijacked Candid's planned reverse merger with Rallybio to challenge Gilead for an emerging opportunity for T-cell engagers.
Nick Paul Taylor May 4, 2026 7:46am
two arrows pointing different directions

Candid scores Nasdaq listing via reverse merger Rallybio

Mar 2, 2026 11:45am
relay

Rallybio shifts gears, cashing out of Recursion pact

Jul 8, 2025 8:59am
scissor cutting rope

RallyBio cuts deeper, laying off 40% of workforce

May 8, 2025 9:00am
crash fall stock shares market economy down red arrow

Rallybio drops lead program as phase 2 data disappoint

Apr 8, 2025 8:52am
calculator calculate budget

Rallybio reins in preclinical, Monopar pivots to radiopharma

May 9, 2024 10:13am